Fziomed, Inc. to Highlight its Adhesion Barrier Gel Product Solutions at the 2025 IFSSH and IFSHT Triennial Global Hand Congress
SAN LUIS OBISPO, California, March 11, 2025 — Fziomed, Inc. (“Fziomed” or the “Company”), a recognized global leader in postsurgical adhesion prevention, today announced it will attend the 2025 IFSSH and IFSHT Triennial Global Hand Congress March 24-28 in Washington, D.C. hosted by the American Society for Surgery of the Hand, American Society of Hand Therapists, and American Association for Hand Surgery. The Company will showcase its Dynaviscâ Adhesion Barrier Gel, the only synthetic dual-polymer technology on the market, designed to reduce adhesion formation following tendon and peripheral nerve surgery.
Fziomed’s absorbable gel adhesion barrier products are based on the Company’s patented dual-polymer technology with more than 20 years of clinical use. Dynavisc provides a temporary physical barrier between tissues helping prevent the formation of adhesions, reducing the incidence of postoperative pain and complications such as limited range of motion. For tendon and peripheral nerve related surgical procedures, Dynavisc and its simple applicator offers ease of use combined with proven safety and clinical efficacy. Join Fziomed at Booth #809 during the Global Hand Congress to learn more.
“Even with the best surgical technique, postoperative adhesions can form following tendon and peripheral nerve procedures including flexor tendon repair, tenolysis, correction of Dupuytren’s contracture, neurolysis, and treatment of carpal tunnel syndrome,” stated Gere diZerega, MD, Fziomed’s Medical Director. “The key to safeguarding patients and maximizing the benefits of their surgical procedures is creating a barrier to reduce the formation of adhesions.”
“We are excited to offer surgeons an easy-to-use and time-tested technology designed to preserve their surgical excellence and provide better outcomes for patients,” commented Paul Mraz, CEO of Fziomed. “Our family of synthetic, absorbable adhesion barrier gels are specifically tailored to complement the procedure and not complicate it.”
Fziomed’s adhesion barrier gels are provided sterile and ready to use with specialized applicators that allow for ease of application while the clear gel formula maintains local visibility. No special storage, refrigeration, mixing, or handling is required.
About Fziomed, Inc.
Pioneering biomaterials since 1996, Fziomed is a vertically integrated medical device company focused exclusively on preserving surgical excellence in spine, tendon/nerve, abdominal/pelvic and intrauterine procedures. Fziomed develops, manufactures, and commercializes surgical biomaterials used by clinicians to improve surgical outcomes and is a global leader in postsurgical adhesion prevention.
Fziomed’s synthetic, absorbable gel formulations are based on the Company’s patented dual-polymer technology platform that provide a temporary, physical separation of tissues during the body’s natural healing process – reducing adhesion formation. Fziomed’s portfolio of adhesion barrier products are marketed in more than 70 countries under various brand names and have been used clinically since 2002 in nearly 1 million procedures worldwide.
Visit fziomed.com to learn more about Fziomed and our industry-leading products. Dynavisc is not yet FDA cleared for use in the United States.
